SARS-CoV-2 Testing From EUROIMMUN

EUROIMMUN, a PerkinElmer, Inc. company, is one of the first companies in the world to offer a comprehensive panel of SARS-CoV-2 tests, validated for in vitro diagnostic purposes. Tests offered include swabs and polymerase chain reaction (PCR) technologies for direct detection of the virus and high accuracy serology methods (ELISA: enzyme linked immunosorbent assay) for the detection of antibodies in patients that have had a previous COVID-19 infection.

EUROIMMUN UK, a subsidiary of EUROIMMUN AG, is based in London and has supported Public Health England (PHE) in establishing a serology assay for use in the National Testing Strategy since March with tens of thousands of tests delivered. The EUROIMMUN tests are being used in a serosurveillance study, the results of which will inform the UK Government’s strategy to combat the pandemic.

Dr Daniel Agustus, Managing Director of EUROIMMUN UK, said:

“We are honoured to support the National Testing Strategy, as our test results assist the Government’s critical decision processes with regards to controlling the spread of the virus and the ability for the country to be able to gradually reopen.”

EUROIMMUN UK expects population testing to increase over the coming weeks and is supporting public health bodies carrying out work for Pillar 4 of the National Testing Strategy in England, Wales, Scotland and Northern Ireland. Following successful ramp up of production over the last weeks, EUROIMMUN UK is now also supporting diagnostic services in all healthcare settings including NHS hospitals.

The IgG antibody test offered by EUROIMMUN is highly accurate and presents a specificity of > 99%, meaning its results are very reliable.

EUROIMMUN UK offers SARS-CoV-2 testing in addition to the diagnostic kits it already provides to detect a range of autoimmune and infectious diseases and allergies.